Recursion Pharmaceuticals (NASDAQ: RXRX), a small-cap biotech company, has one claim to fame: It currently owns the largest ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Objective: Acute respiratory distress syndrome (ARDS) is a common complication in patients with non-pulmonary sepsis. Early identification and prediction of the occurrence of ARDS in non-pulmonary ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Abstract: This article deals with the recursive quadratic filtering problem for a class of linear discrete-time systems with the random access protocol (RAP) and non-Gaussian noises (NGNs). In order ...

It’s no secret that much of social media has become profoundly dysfunctional. Rather than bringing us together into one utopian public square and fostering a healthy exchange of ideas, these platforms ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Ever wondered how social media platforms decide how to fill our feeds? They use algorithms, of course, but how do these algorithms work? A series of corporate leaks over the past few years provides a ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...